Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk
Condition: To Evaluate the Rate of Digestive and Urinary Toxicity Intervention: Radiation: prostatic boost in brachytherapy with high dose rate (HDR) Sponsor: Centre Georges Francois Leclerc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials